31results about How to "Suitable as therapeutic" patented technology

A stent made of a self-expandable or balloon-expandable metal mesh fabric that can be widened to a diameter larger than that of the descending aorta. The stent has a flexible lining of vessel-replacing material, wherein the lining covers it at least partly in longitudinal direction and forms a tubular segment which projects beyond the end of the stent at least at one end and which functions as the vascular prosthesis. Such implantable arrangements (1) make it possible to achieve short surgical times, especially during the treatment of aortic arch aneurysms involving the cephalic arteries.

A method and material for augmenting the shape and thickness of the cornea in situ includes applying a clear liquid collagen mixed with a customized crosslinker onto the augmentation surface or in a cavity (with or without a mold) and exposing the mixture to UVA radiation in vivo. Application of UVA at varying dosages demonstrate progressive optically clear gelation and biomechanical adherence properties, and in vitro optical properties (RI), mechanical suture strength and rheometric parameters are comparable to native corneal stromal tissue. Photochemical corneal collagen augmentation according to the invention makes it suitable to reconstruct and strengthen diseased and damaged eyes, ulcerated corneas, as well as provide a substrate for refractive onlay / inlay procedures and lamellar transplantation.

The present invention relates to compositions and methods for the delivery of therapeutic proteins to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering proteins into the cerebrospinal fluid of mammalian subjects through peripheral administration of AAV vectors. The invention may be used to treat various disorders of the central nervous system, including degenerative diseases and motor neuron diseases.

The present disclosure relates to a method for controlling a magnetic resonance imaging guided radiation therapy apparatus comprising a magnetic resonance imaging system. The method comprises: acquiring magnetic resonance data using the magnetic resonance imaging system and the pulse sequence from an imaging volume; segmenting the magnetic resonance data into a plurality of segments indicating respective tissues in the imaging volume; creating a bulk electron density map of the imaging volume from the plurality of segments; displaying the bulk electron density map and radiation dose distributions for the plurality of segments on a graphical user interface, wherein the radiation dose distributions are determined using the bulk electron density map; receiving a modification signal for modifying at least a first segment of the segments; recreating the bulk electron density map using the modified first segment, and recalculating the radiation dose distribution using the bulk electron density map; redisplaying the bulk electron density map and the radiation dose distributions on the graphical user interface.

The present invention provides coated sustained release tablets of a hygroscopic compound for once-a-day therapy, said tablets having a moderate weight and volume and comprising-(a) a core comprising the hygroscopic compound and pharmaceutically acceptable excipients, (b) a first coating layer comprising a polymer selected from the group consisting of water-insoluble polymers, pH dependent polymers or a mixture thereof, and (c) a second coating layer comprising a water-insoluble polymer.

The present invention relates to various pharmaceutical compositions that can be used as active or passive vaccines for the treatment or prevention of fungal disease. Methods for prevention and treatment of infectious and allergic fungal diseases in subjects using the pharmaceutical compositions of the present invention are also disclosed.

The invention provides stable solid compositions of a therapeutic agent, such as a protein, (e.g., an antibody, a peptide, or a DVD-Ig protein), and a stabilizer, such as a sugar, and methods of preparing and using the same. The invention further provides a generalized therapeutic agent delivery form wherein the active components are in a lyophilized, stable configuration, and, in some embodiments, prepared independently from the primary container.

A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and rises of the compound, particularly in antisense therapy.

A process for preparing a thermosensitive polymer from a microemulsion is provided. The microemulsion comprises a monomer capable of forming a thermosensitive polymer and a polymerizable surfactant. Additional comonomers may be included in the microemulsion to vary the properties of the polymers produced. The resulting thermosensitive polymers may be nanoporous. The polymers according to the invention are suitable for use in medical applications, including use as a wound dressing and for delivery of cells to a graft site.

A method and system for fully automatic segmentation the prostate in multi-spectral 3D magnetic resonance (MR) image data having one or more scalar intensity values per voxel is disclosed. After intensity standardization of multi-spectral 3D MR image data, a prostate boundary is detected in the multi-spectral 3D MR image data using marginal space learning (MSL). The detected prostate boundary is refined using one or more trained boundary detectors. The detected prostate boundary can be split into patches corresponding to anatomical regions of the prostate and the detected prostate boundary can be refined using trained boundary detectors corresponding to the patches.

The present disclosure provides engineered human extracellular DNASE proteins (e.g., variants of DNASE1 (D1), DNASE1-LIKE 1 (D1L1), DNASE1-LIKE 2 (D1L2), DNASE1-LIKE 3 Isoform 1 (D1L3), DNASE1-LIKE 3 Isoform 2 (D1L3-2), DNASE2A (D2A), and DNASE2B (D2B)) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and / or release. In accordance with the invention, the DNase variant has advantages for therapy and / or large-scale manufacturing.

The invention provides methods for differentiating stem cells along the pancreatic lineage as well as large scale culture methods. The present invention further provides pancreatic progenitor cells derived from stem cells to provide pancreatic cells to a subject.

The invention relates to a method for the diagnosis or prognosis of a cancer comprising (i) determining a level of expression of Myb-related transcription factor (MYPOP) or a part thereof in a patient sample; (ii) comparing the level of MYPOP expression of the patient sample to levels of a normal sample; (iii) correlating the level of MYPOP expression in the patient sample relative to the levels in the normal sample with a positive or negative diagnosis or prognosis of cancer.

Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.

The present invention relates to the use of a vehicle for specific molecular targeting of Langerin+ cells, wherein the vehicle is capable of specifically binding to a Langerin+ cell, said vehicle comprising (a) at least one carrier and (b) at least one saccharide moiety-based conjugate for a targeted cargo delivery into a Langerin+ cell, as well as pharmaceutical compositions and uses comprising the inventive vehicle.

Disclosed herein are monoclonal antibodies or binding portion thereof that bind specifically to a Staphylococcus spp. autolysin N-acetylmuramoyl-L-alanine amidase catalytic domain and / or cell wall binding domain, as well as pharmaceutical compositions containing the same. Cell lines expressing the monoclonal antibodies, including hybridomas, are also disclosed. Methods of using the monoclonal antibodies for installation of orthopedic implants, grafts or medical devices, treating or preventing a Staphylococcus infection, and treating osteomyelitis are described, as are diagnostic methods for the detection of Staphylococcus in a sample.

The beam irradiation apparatus is featured by including a transport pipe which is vacuum-evacuated to be used as a transport channel of a beam taken out from an accelerator, a quadrupole magnet which modulates the beam diameter of the beam so that the beam is incident on an irradiation target existing in the atmosphere while maintaining the focusing angle of the beam, and one or more longitudinally movable range shifters which are provided to be capable of changing the distance to the irradiation target of the beam, and which modulate the beam range by reducing the energy of the beam by allowing the beam to pass through the movable range shifter, and is featured in that the beam is irradiated onto the irradiation target by modulating the beam diameter and the beam range.